Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2 inhibitor effects on sympathetic nerve activity in type 2 diabetes
jRCTs041200035Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Oct 2020
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised trial in type 2 diabetes mellitus (T2DM) comparing Luseogliflozin arm with Glimepiride arm (2 arms). Primary endpoint: Change in muscle sympathetic nerve activity. Started Oct 2020; status: completed.
02
Drugs
luseogliflozinglimepiride
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs041200035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041200035.